Bullfrog AI Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $298.8K+359.7% YoYTTM through 30 Jun 2026
Net Income -$6MTTM through 30 Jun 2026
Free Cash Flow -$5.5MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 18.7% |
| Operating Margin | -5,636.4% |
| Net Margin | -2,006.9% |
Returns
-304.2%ROE
Balance Sheet Health
Debt / Equity0.00x
Current Ratio3.85x
Net Debt-$2.2Mnet cash position
Cash & Equivalents$6.9M
Quality Metrics
Altman Z-Score3.15
Piotroski F-Score4 / 9
FCF Margin-1,840.5%
Rule of 40-1,823.4
Multi-Year Trend
RevenueFY2025: $116.7K
Diluted EPS-$0.46TTMFY2025: $-0.63
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| AI-driven Drug Discovery and Development | $117K | View detailsThe company aims to expand commercial activity and partnerships with global pharmaceutical and biotechnology partners using its bfLEAP platform. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.